[go: up one dir, main page]

MX2023001199A - Antagonistas de receptor nk para pacientes con cancer. - Google Patents

Antagonistas de receptor nk para pacientes con cancer.

Info

Publication number
MX2023001199A
MX2023001199A MX2023001199A MX2023001199A MX2023001199A MX 2023001199 A MX2023001199 A MX 2023001199A MX 2023001199 A MX2023001199 A MX 2023001199A MX 2023001199 A MX2023001199 A MX 2023001199A MX 2023001199 A MX2023001199 A MX 2023001199A
Authority
MX
Mexico
Prior art keywords
receptor antagonists
cancer patients
cancer
vms
attenuating
Prior art date
Application number
MX2023001199A
Other languages
English (en)
Inventor
D Christopher Schelling
Robert A Steiner
Susan D Reed
Victor M Navarro
Original Assignee
Acer Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acer Therapeutics Inc filed Critical Acer Therapeutics Inc
Publication of MX2023001199A publication Critical patent/MX2023001199A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción se refiere en general a un método para bloquear, atenuar o limitar el desarrollo de uno o más síntomas vasomotores (SVM) en un paciente que tiene cáncer, ha tenido cáncer o tiene un mayor riesgo de cáncer mediante la administración de un antagonista de NK.
MX2023001199A 2020-07-30 2021-07-30 Antagonistas de receptor nk para pacientes con cancer. MX2023001199A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063059086P 2020-07-30 2020-07-30
US202163134542P 2021-01-06 2021-01-06
PCT/US2021/044016 WO2022026900A2 (en) 2020-07-30 2021-07-30 Nk receptor antagonists for cancer patients

Publications (1)

Publication Number Publication Date
MX2023001199A true MX2023001199A (es) 2023-03-13

Family

ID=80036164

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001199A MX2023001199A (es) 2020-07-30 2021-07-30 Antagonistas de receptor nk para pacientes con cancer.

Country Status (5)

Country Link
US (1) US20230277518A1 (es)
AU (1) AU2021315801A1 (es)
CA (1) CA3189841A1 (es)
MX (1) MX2023001199A (es)
WO (1) WO2022026900A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023147134A2 (en) * 2022-01-31 2023-08-03 Acer Therapeutics, Inc. Methods for treating patients having low estrogen with nk3 antagonists
JP2025514162A (ja) * 2022-04-25 2025-05-02 キャリーオペ，インク． Ｎｋ３モジュレーターによる頭痛障害の処置
CN121399122A (zh) 2023-04-18 2026-01-23 卡尔优普公司 Nk3调节剂及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002535274A (ja) * 1999-01-25 2002-10-22 スミスクライン・ビーチャム・コーポレイション 抗アンドロゲン剤および疾病の治療方法
CA2412355A1 (en) * 2000-06-12 2001-12-20 University Of Rochester Method of treating symptoms of hormonal variation, including hot flashes, using tachykinin receptor antagonist
AU2002259147A1 (en) * 2001-05-08 2002-11-18 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
WO2003037334A1 (en) * 2001-10-31 2003-05-08 Merck & Co., Inc. Method for treating or preventing symptoms of hormonal variation including hot flashes
US20150272927A1 (en) * 2012-12-03 2015-10-01 University Of Washington Through Its Center For Commercialization Methods and compositions for treating vasomotor symptoms
GB201315846D0 (en) * 2013-09-05 2013-10-23 Imp Innovations Ltd Method for treating or preventing hot flushes
AU2015228859A1 (en) * 2014-03-13 2016-07-07 F. Hoffmann-La Roche Ag Therapeutic combinations with estrogen receptor modulators
KR102704783B1 (ko) * 2015-05-18 2024-09-10 칸디 테라퓨틱스 리미티드 성-호르몬 의존성 질환의 치료를 위한 이중 nk-1/nk-3 수용체 길항제

Also Published As

Publication number Publication date
WO2022026900A2 (en) 2022-02-03
US20230277518A1 (en) 2023-09-07
CA3189841A1 (en) 2022-02-03
WO2022026900A3 (en) 2022-04-21
AU2021315801A1 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
MX2023001199A (es) Antagonistas de receptor nk para pacientes con cancer.
MX2022001247A (es) Metodos para tratar dermatitis atopica mediante la administracion de un antagonista il-4r.
WO2019099639A8 (en) Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
CL2020002075A1 (es) Métodos para tratar el cáncer con anticuerpos anti-pd1.
PH12021550882A1 (en) Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
ZA202204929B (en) Rimegepant for cgrp related disorders
MX2020013335A (es) Metodos novedosos.
BR112020015915A8 (pt) Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer
MX2015012520A (es) Ensayos y metodos para seleccionar un regimen de tratamiento para un sujeto con depresion.
TW200605907A (en) Preventing autoimmune disease
MX2021013427A (es) Metodos para tratar o prevenir el asma mediante la administracion un antagonista de il-33.
MX2019001814A (es) Tratamiento y remision virologica sostenida de infeccion de vih mediante anticuerpos a cd4 en pacientes estabilizados con haart.
MX2023003942A (es) Metodos para el tratamiento del asma en sujetos pediatricos mediante la administracion de un antagonista del il-4r.
MX2023000763A (es) Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrofilas.
MY204185A (en) Composition and methods for the treatment of myopia
MX390722B (es) Tratamiento de resistencia a diureticos.
MX2024001189A (es) Metodos para tratar la urticaria cronica espontanea por administracion de un antagonista de il-4r.
MX2024013184A (es) Metodos y composiciones para tratar apnea del sue?o
MX2025005240A (es) Métodos para el tratamiento de la nefritis lúpica mediante el uso de antagonistas de fcrn
WO2016014799A9 (en) Epidermal growth factor and blockade of immune checkpoints in cancer immunotherapy
MX2019001467A (es) Combinación de antagonistas del receptor de glucagon e inhibidores de la trayectoria p13k para el tratamiento del cáncer.
MX2021003689A (es) Farmacos precursores de antagonistas del peptido relacionado con el gen para calcitonina (gcrp).
PH12022553376A1 (en) Acalabrutinib maleate dosage forms
MX2024004762A (es) Metodos para el tratamiento del prurigo nodular mediante la administracion de un antagonista de il-4r.
Eertink et al. The optimal timing of interim 18F-FDG PET in diffuse large B-cell lymphoma: An individual patient data meta-analysis by the Petra consortium